Syn-One Test®

A Simple Skin Biopsy Can Aid the Diagnosis of Parkinson's Disease

Identifying Parkinson's Disease Can Be Challenging.

The Syn-One Test provides objective visual proof of phosphorylated alpha-synuclein (P-SYN), a key marker of Parkinson's disease (PD), aiding diagnosis and informed patient care.

In 2025, a review article on Parkinson's disease, published in the American Academy of Neurology's journal *Continuum,* highlighted skin biopsy as an essential tool when diagnostic uncertainty exists, noting that alpha-synuclein detection may aid early PD diagnosis.[1]

WHY CHOOSE THE SYN-ONE TEST?

- A simple, minimally invasive in-office procedure
- Confirms the presence of P-SYN with high reliability[2]
- Supports enhanced clinical decision-making, useful in patients with[3]:
  - unclear clinical presentation or diagnosis
  - unexpected response to medication
  - atypical symptom progression

PROVEN RESULTS

- 92.7% positivity rate in patients with clinically confirmed Parkinson's disease[2]
- Greater than 95% positivity in other synucleinopathies[2]*

*Prospective, blinded study (N=428) demonstrated 95.5% sensitivity and 96.7% specificity rates across synucleinopathies.

92.7% Positivity Rate in Identifying P-SYN in Patients With Parkinson's Disease[2]

Learn more about the Syn-One Test at cndlifesciences.com

1.Rawls AE, Okun MS. Parkinson Disease. *Continuum (Minneap Minn)*. 2025;31(4):930-955. doi:10.1212/cont.0000000000001593
2.Gibbons CH, Levine T, Adler C, et al. Skin biopsy detection of phosphorylated α-synuclein in patients with synucleinopathies. *JAMA*. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792
3.Data On File: Survey of US physicians currently using the Syn-One Test (n=78); conducted by ClearView Healthcare Partners, 2023.

The Syn-One Test is a Laboratory Developed Test (LDT) performed in a CLIA-certified laboratory. It is not FDA-cleared or approved.

CND Life Sciences®
Diagnostic Insights for Life